I’d say we are hands off for now. Maybe a partne

I’d say we are hands off for now. Maybe a partner way down the road but I think they shifted focus, maybe why no MASH TAG. It’s done on our end. Fat on the liver is the start of MASH. I don’t think we can treat MASH on our own. Ohm can you chime in please. I’m curious as well.

Pivot to fibrous of other organs or maybe MASH set is set aside for now until someone wants to take the risk to fund it. MASH is such a big undertaking. I think we hit the pause button until someone else wants to take it on. That’s how I read it.

Daniel Rizzo
Founder & CEO | FireGate Biotech™
AI Platform: Lux Veritas™

Federal Whistleblower Case References
• HHS & SEC Whistleblower ID – HL-1412396
• DOJ Investigation Report / Whistleblower ID – 20250705-0001
• NIH Case Reference – CS1137565 ( IC IG / 50 U.S.C. § 3033 )

Website: FireGateBiotech.com
(For official updates and correspondence — I will no longer be posting here or responding via DMs)

Contact FireGate Biotech

Principal Investigator:
FG001|FG002|FG003

https://zenodo.org/records/17290045?token=eyJ...UkeT_EvKIQ


https://firegatebiotech.com/2025

https://zenodo.org/records/17291133?token=eyJ...kN7msthgMA





— Jeremiah 51:36